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Abstract
Since the mid 1970s, cancer has been described as a process of Darwinian evolu-
tion, with somatic cellular selection and evolution being the fundamental pro-
cesses leading to malignancy and its many manifestations (neoangiogenesis,
evasion of the immune system, metastasis, and resistance to therapies). Histori-
cally, little attention has been placed on applications of evolutionary biology to
understanding and controlling neoplastic progression and to prevent therapeutic
failures. This is now beginning to change, and there is a growing international
interest in the interface between cancer and evolutionary biology. The objective
of this introduction is first to describe the basic ideas and concepts linking evolu-
tionary biology to cancer. We then present four major fronts where the evolu-
tionary perspective is most developed, namely laboratory and clinical models,
mathematical models, databases, and techniques and assays. Finally, we discuss sev-
eral of the most promising challenges and future prospects in this interdisciplin-
ary research direction in the war against cancer.
© 2012 The Authors. Published by Blackwell Publishing Ltd. This is an open access article under the terms of the Creative
Commons Attribution License, which permits use, distribution and reproduction in any medium, provided
the original work is properly cited.
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Introduction
In 1971, the US president Richard Nixon declared the now
famous ‘war on cancer’, predicting victory within 5 years.
Forty years later, cancer still accounts for about one-
quarter of human deaths in wealthy countries and about
one-eighth worldwide (World Health Organization 2008).
Despite significant progress, treatments have not met
expectations and cancer research is now at a crossroad,
needing new ideas, major innovation, and new and unprec-
edented transdisciplinary teams of scientists (Drake 2011).
Although the theory of cancer initiation and progression is
deeply rooted in evolutionary and ecological concepts
(Cairns 1975; Nowell 1976), many promising opportunities
for the application of evolutionary biology to oncology
remain unexplored. To what extent does evolutionary the-
ory provide a useful framework for understanding and pre-
dicting cancer progression in laboratory and clinical
settings, and is it more applicable to certain cancers rather
than others? What level of mathematical sophistication is
necessary to investigate observations and will this require
stochastic components, meaning less predictability? Can we
alter the competition between cancerous and healthy cells
by boosting the fitness of benign cells? What are the selec-
tive effects of therapies?
The important challenges in cancer research are to
understand susceptibility, emergence, and progression, and
to predict treatment outcomes, including the major prob-
lem of relapse, given both limited individual-level informa-
tion and data from past clinical cases and laboratory
studies. Whereas enormous progress has been made in
understanding cell-autonomous molecular mechanisms of
oncogenic transformation, our vision of tumor–host inter-
actions is still in its infancy. Specifically, we know that the
vast majority of cells that have initiated an oncogenic trans-
formation will be eliminated by the host, but we lack the
capacity to predict which will escape the surveillance mech-
anisms (Folkman and Kalluri 2004; Bissell and Hines
2011). Our increased capacity to detect precancerous
lesions and circulating or dormant tumor cells is, thus, dif-
ficult to put into practice. Indeed, as exemplified by a
recent controversy regarding early diagnosis of prostate
cancer (Cooperberg et al. 2011; see also Epstein et al. 2001
for breast cancer), a strategy to aggressively target all pre-
cancerous or dormant cancerous cells carries the risk of
overtreatment, when active surveillance may be a safer and
acceptable alternative. Thus, while we need further
advances in the description, classification, and understand-
ing of molecular mechanisms of cancer, we must strive to
meet additional challenges, such as, for instance, our capac-
ity to predict and model the interrelationships between the
tumor and its environment at different scales (Bissell and
Hines 2011).
While defining the probability of progression of early
lesions to full-blown cancer is a major challenge in cancer
research, it must be emphasized that today most patients
are diagnosed when their disease is at an advanced, meta-
static stage (reviewed in Valastyan and Weinberg 2011).
From the clinical standpoint, it is thus of the utmost
importance to develop efficient therapies to fight tumor cell
proliferation with minimal side effects and to either man-
age or prevent the emergence of resistance in neoplastic cell
populations. In this respect, ecological and evolutionary
approaches have contributed with mathematical models
(Gatenby and Vincent 2003; Komarova and Wodarz 2005;
Foo and Michor 2009; Gatenby et al. 2009; Cunningham
et al. 2011; Lorz et al. in press; Hochberg et al. this
volume) yielding predictions such as (i) evolving neo-
plasms and microenvironments may thwart cell-targeted
therapies (Gillies et al. 2012), (ii) multiple therapeutic tar-
gets are less likely to result in resistance than monothera-
pies (Komarova and Wodarz 2005; Lorz et al. in press),
and (iii) developing preventive therapies with minimal side
effects may control or eliminate incipient lesions and neo-
plasms, and prevent the emergence of chemoresistant lin-
eages (Hochberg et al. this volume).
The objective of this special issue is to continue the con-
struction of a broad base for a more balanced approach to
cancer research, by assembling some of the latest, most
exciting results, syntheses, and perspectives relating to the
action of natural selection and drift in determining evolu-
tionary dynamics and emergent patterns in cancer. Emer-
gent patterns include, but are not limited to, interspecific
differences in cancer susceptibility and tumor suppression,
cancer initiation, and progression, and cancer therapies.
Evolutionary biology in the study of cancer
An important conceptual breakthrough in understanding
cancer lies in Darwinian and ecological theories: cancer is a
disease of opportunity, associated with clonal evolution,
expansion, and competition within the body (Cahill et al.
1999; Merlo et al. 2006; Greaves and Maley 2012). Specifi-
cally, somatic cellular selection and evolution are the funda-
mental processes leading to malignancy, metastasis, and
resistance to therapies, with the contribution of cancer stem
cells as the progenitors of these more differentiated cell types
(Shipitsin and Polyak 2008; Greaves this volume). However,
it is not known whether patients relapse because cancer stem
cells are intrinsically resistant to therapy, and/or because
therapy selects for resistance or, most likely, both. An addi-
tional complication is the tremendous plasticity of cancer
cells and their ability to acquire stem cell characteristics
through deregulated expression of just a few genes (Takah-
ashi and Yamanaka 2006; Mani et al. 2008; Morel et al.
2008). This phenomenon notwithstanding, tumors can be
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viewed as collections of individuals (cells) that accumulate
genetic and epigenetic changes, and through their interac-
tions with the environment (selection), adaptively evolve.
Examples include stressful microenvironments affecting the
evolution of the invasive phenotypes (Lee et al. 2011), and
the evolution of resistance to toxicity during tumor growth,
providing a competitive advantage with respect to wild-type
cells (Gatenby et al. 2006; Vineis and Berwick 2006). Epige-
netic changes have been recognized as neoplasm markers
since the 1980s (Romanov and Vanyushin 1981); however,
their role is still elusive. Some see them as a byproduct of
deregulated gene expression, others as initial event in onco-
genesis. Only very recently, epimutations were included in
mathematical models that attempt to describe the evolution
of tumors (Iwami et al. 2012). Transient increases in epige-
netic mutations as a result of stressful environments could
provide a solution to the conundrum that rapid evolution
of somatic cells into neoplasms would require very high
mutation rates, placing them at risk of extinction due to
excessive levels of (epi)genetic instability (Cahill et al. 1999;
Sole´ and Deisboeck 2004).
Based largely on cytological, molecular, and genetic stud-
ies, researchers have recently argued that cancers should be
viewed both as genetically and phenotypically heteroge-
neous populations within individuals (Marusyk and Polyak
2010) and as different ‘species’ between individuals (Merlo
and Maley 2010; Gatenby 2011). This variability suggests
that stochastic and complex interactive forces reduce our
ability to make generalizations about different stages in
carcinogenesis. Mechanisms that could generate this vari-
ability are mutations, chromosomal damage, including cat-
astrophic events such as recently described chromotripsis
(Stephens et al. 2011), deletions and duplications, heritable
changes in gene expression, DNA methylation, and changes
in protein conformation (Maley et al. 2006). Interestingly,
recent sequence data from a large number of different
tumor types have revealed the frequent occurrence of
events affecting global control of cellular functions, for
instance, changes in chromatin modifications or RNA pro-
cessing (recently reviewed in the study by Ma et al. 2012),
likely to impact the rate of tumor evolution. Tarafa et al.
(2003) showed that chromosomal instability arises early in
cancer progression, and that major genetic changes tend to
occur in one of a few particular orders, meaning that
some level of predictability in key events may be possible
for some cancers. Progress in phylogenetic reconstruction
(Gerlinger et al. 2012), inference methods (Riester et al.
2010), agent based modelling (Sprouffske et al. 2011),
and whole genome sequencing (Parmigiani et al. 2009)
will be key to untangling and reconstructing somatic
evolutionary pathways. A major unresolved question,
therefore, is whether a single overarching framework can
incorporate observed variability and make cancer a more
predictable phenomenon both at individual and popula-
tion levels.
Evolutionary and ecological theory has already proven
useful in our understanding of cancer, but many basic parts
of the puzzle are missing. We need to know how variation
is created and selected for, and the adaptive consequences
of interactions between environments and genes. We also
need to understand the relative roles of stem cells and
differentiated cells in cancer dynamics (Visvader and Lind-
eman 2008; Greaves this volume), taking into account the
cellular plasticity that might render the distinction between
the two largely artificial. Perhaps, the greatest challenge is
to understand the relevance of processes occurring at one
scale for patterns at another (Tomlinson and Bodmer
1999). For example, it is increasingly recognized that many
cancers are associated with chronic inflammation, aging,
and changes in local microenvironments, and in tissue
structure and architecture (Polyak et al. 2009; Bissell and
Hines 2011; Gatenby 2011). Are these phenomena causes
and/or consequences of genetic instability and progression,
or less interestingly, correlations without demonstrable
causation?
Evaluating current theories and advancing new hypothe-
ses will require use of the latest techniques and the develop-
ment of new approaches. Four major fronts have proved
indispensable to cancer research.
Laboratory and clinical models
There is ample evidence of intratumor clonal heterogeneity
in human cancer (recently reviewed in Marusyk et al.
2012), with many examples from hematopoietic malignan-
cies and from solid tumors. There are ongoing efforts
worldwide to provide a comprehensive description of
genomic, transcriptomic, and epigenomic profiles of a large
number of tumors (International Cancer Genome Consor-
tium 2010). Whereas such global analyses will undoubtedly
lead to a better understanding of the complexity of tumor
cell populations, there is also a need for model systems that
are simpler to analyze and possible to manipulate. The sim-
plest of such models consists of analyzing two or more
genetically distinct tumor clones grown in coculture under
different environmental constraints. More ambitiously, the
tumor microenvironment can be mimicked in culture, for
example, by constructing three-dimensional models with
controlled physicochemical characteristics of the extracellu-
lar matrix (reviewed in Egeblad et al. 2010). Finally, in vivo
animal models are particularly attractive for studies of
tumor growth and evolution. For example, mammary
tumors inoculated into cleared fat pads (Mani et al. 2008;
Fridriksdottir et al. 2011) or hepatic tumorigenesis follow-
ing intrasplenic injection of transformed cells (Zender et al.
2006) have already provided a wealth of information. Such
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models carry rich opportunities for studying complex
interactions between cell clones.
While cellular competition is the issue most often
addressed, other types of interactions, with possible major
clinical impacts have also been observed. For example, it
has recently been reported that an apoptosis proficient
clone provides an advantage to a tumor relapse through
stimulation of growth via paracrine signaling from cells
dying after radiation therapy (Huang et al. 2011). From an
evolutionary perspective, however, an additional complica-
tion comes from a recent finding that subtle differences in
the precise mechanism of programmed cell death give rise
to diametrically opposed consequences of the host immune
reaction toward the dying cells (Green et al. 2009). Under-
standing how selection drives the evolution of complex
interactions between cell clones remains a challenging
question.
Mathematical models
Mathematical models are important tools for characteriz-
ing the complexity of cancerogenesis and the underlying
role of evolutionary processes (Foo and Leder this volume).
There are various ways for models to include the rich and
puzzling biological diversity that may be observed in tumor
spatial and temporal heterogeneity, and whenever possible
to identify evolutionary trends, aiming at prediction and
control, in particular, for practical therapeutic purposes in
oncology.
Nevertheless, computer simulations are never proofs,
even though they can give hints to what can actually be
proven by mathematics. The simplest mathematical models
aim at describing a well-characterized situation by sets of
ordinary differential equations or probabilistic branching
processes (Iwasa et al. 2006; Foo and Michor 2009; Toma-
setti and Levy 2010) and yield answers to important prob-
lems such as the prediction of drug resistance. As regards
more physiologically detailed models designed to predict
cell population behavior, there are two main streams of
models: agent-based stochastic models and spatially or
physiologically structured continuous deterministic mod-
els. Agent-based models (Anderson et al. 2006) include
stochastic rules that decide how a whole cell population
passes from stage i to stage i + 1, by taking into account all
individual cell behaviors. Spatially or physiologically struc-
tured continuous deterministic population models are
based on partial differential or integrodifferential equations
and consider the population as a whole, structured accord-
ing to a continuous variable that can be space (Frieboes
et al. 2006, 2009), but also molecular content in a protein,
or level of expression of a phenotypic trait (Lorz et al.
2012), etc., that has been selected as relevant to describe
population heterogeneity. Continuous deterministic
population models are not limited by computer perfor-
mance, which is not the case for agent-based models; con-
versely, agent-based models are more flexible than simpler
deterministic models and may take into account virtually
any local biological phenomenon. Comparisons between
the two approaches have been made (Byrne and Drasdo
2009; Osborne et al. 2010), pointing out their respective
advantages and drawbacks.
Models of these different types have simulated a range of
the many facets of tumor biology, for example, stem cell
dynamics (van Leeuwen et al. 2007; Michor 2008; Sottoriva
et al. 2011), the stochastic emergence of resistance during
clonal expansion (Iwasa et al. 2006), the numerical dynam-
ics of differentiated cell types (Dingli et al. 2007), metasta-
sis (Gatenby and Vincent 2003; Frieboes et al. 2006;
Michor et al. 2006), and therapeutic outcomes (Michor
et al. 2005; Frieboes et al. 2009; Gatenby et al. 2009). These
models have been successful in evaluating hypothetical
scenarios in adaptation to different microenvironmental
challenges, such as hypoxia and acidosis (Anderson et al.
2006; Gatenby et al. 2006), and to chemotherapy (Michor
et al. 2005; Foo and Michor 2009; Cunningham et al.
2011). There has been a recent surge in models integrating
observations and experimental data (Frieboes et al. 2009;
Bozic et al. 2010; Byrne 2010) and next-generation models
capable of simulating highly detailed somatic genetic events
(Stephan-Otto Attolini et al. 2010; Sprouffske et al. 2011).
Databases
Numerous international and national databases are now
available online relating to several socioeconomic and
health topics, including statistics on cancer incidence and
mortality worldwide, or cancer mutations and copy num-
ber variation (CNV; International Agency for Research on
Cancer (IARC GLOBOCAN project, 2008, http://globocan.
iarc.fr/; http://www.biologie.uni-hamburg.de/b-online/
library/genomeweb/GenomeWeb/human-gen-db-mutation.
html; http://gwas.biosciencedbc.jp/cgi-bin/cnvdb/cnv_top.
cgi). Such databases provide a unique opportunity to con-
duct comparative analyses at the largest scale to explore or
validate various hypotheses on cancer origin and/or
dynamics. For instance, macroecological approaches have
been recently employed to study the infectious causation of
certain cancers (Thomas et al. 2011, 2012a; Vittecoq et al.
2012) or to explore the evolutionary links between malig-
nancies and birth weight (Thomas et al. 2012b).
Techniques and assays
Techniques originally used to reconstruct the evolutionary
history of species have been applied to tracing the somatic
lineages of healthy and cancerous cells within an individual.
© 2012 The Authors. Published by Blackwell Publishing Ltd4
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State of the art genetic, molecular, cellular, and biochemical
technologies have been applied to study tumor clonality,
plasticity and, evolution. This is in fact a major issue for
tumor characterization, due to problems of representative
sampling (Marusyk and Polyak 2010; Navin et al. 2011).
Currently, major progress in tumor characterization comes
from the generalized use of global genomic and postge-
nomic analyses (next-generation sequencing, transcripto-
mics, proteomics). Two complementary strategies are
currently being developed to address tumor heterogeneity:
multiple comparisons of single cells from macrodissected
tumors (Navin et al. 2010, 2011) and the development of
analytical methods to infer cell populations from unmixed
tumor-wide gene expression or SNP data (Subramanian
et al. 2012). While these technologies have become widely
available and technically reliable, their usefulness is largely
determined by careful definition of biological samples and
models under study. Apart from cancer cell lines, this
research relies on human fresh tumor samples being frozen
and stored in highly specialized biorepositories. To be use-
ful, samples need to be linked with clinical data, and this is
a major challenge given the complexity of different ethical
laws in different countries (Riegman and van Veen 2011).
Challenges and future prospects
Ecology and evolutionary biology as scientific fields have,
until now, developed in relative isolation from the health
sciences. This is unfortunate because links between these
areas have the potential to reveal new perspectives and ave-
nues for fundamental research (Daoust et al., Khalid et al.
this volume). Evolutionary processes and their relevance to
the biology and epidemiology of disease also hold the
promise of instructing on more applied health issues, offer-
ing scientific reasons for why certain medical approaches
are more successful than others. Understanding basic scien-
tific processes could be translated into huge progress for
therapies. For instance, understanding the proliferative and
survival effects due to chimeric tyrosine kinase (bcr-abl) in
Chronic Myelogenous Leukemia has led to a targeted ther-
apy, transforming the prognosis of this lethal disease. Simi-
larly, systematic screening for acquisition of further bcr-abl
mutations permitted to anticipate escape of subclones and
rapidly administer second generation TK inhibitors, thus
restoring drug sensitivity (Gibbons et al. 2012). The tradi-
tional separation between subdisciplines is a fundamental
limitation that needs to be overcome if complex processes,
like oncogenesis, are to be understood. Below, we present
some of the most important current challenges amenable
to ecological and evolutionary approaches to understand
major fundamental and therapeutic aspects of cancer.
Recent reviews on these and related topics can be found in
the studies by Merlo et al. (2006), Pienta et al. (2008),
Gerlinger and Swanton (2010), Caulin and Maley (2011),
Greaves and Maley (2012), Aktipis et al. (2011).
Ecology: infectious agents and cancer
The World Health Organization currently estimates that
20% of cancers are caused by infectious agents, with special
emphasis on viruses and bacteria. Identifying infectious
agents that directly or indirectly contribute to oncogenesis
remains a priority in the war on cancer for an obvious rea-
son: insofar as infectious diseases are preventable or treat-
able, cancers associated with infection could be preventable
as well (De Martel and Franceschi 2009; Ewald and Ewald
this volume). Persistent infections may promote cancer
because long-term host defensive responses induce inflam-
mation that subsequently increases mutation rates (Fitzpa-
trick 2001). In addition, intracellular pathogens may
manipulate their host cells in ways that disrupt traditional
cell barriers to cancer, allowing oncogenic mutations to
accumulate through time. Current evidence links Epstein–
Barr virus, Hepatitis B and C viruses, the bacteria Helicob-
acter pylori, human papilloma virus, and the trematodes
Schistosoma haematobium, S. japonicum, and S. mansoni to
cancers of the lymph nodes, liver, stomach, cervix, bladder,
colon, and liver, respectively. The complete list of onco-
genic pathogens is probably far from being fully established
(Ewald 2009; zur Hausen 2009; Dapito et al. 2012), and
certain scientists speculate that most cancers may have an
infectious origin (Ewald 2009).
Evolution: selection for cancer suppression at the
organism level
Why are some species and/or individuals more at risk than
others to particular cancers? Answering this question neces-
sitates we understand the ecological and evolutionary bases
of cancer vulnerabilities. Comparing cancer incidence
among wildlife species is currently considered a promising
research direction to highlight the natural defenses against
cancers retained by natural selection, and to ultimately
improve cancer prevention in humans (Caulin and Maley
2011). This requires that we resolve Peto’s paradox (Peto
et al. 1975): the lack of a correlation between body size (or
longevity) and cancer across species (Roche et al. this vol-
ume; Nunney, this volume). If each dividing cell in a multi-
cellular organism has the same probability of initiating a
malignant neoplasm, then all else being equal, the more
cells an organism has, the greater the chance of a cancer
emerging. Moreover, transitions to malignancy are
expected to increase with the number of cell divisions –
that is with organism lifespan. Numerous studies have
shown correlations between longevity and body size,
making Peto’s paradox all the more difficult to resolve
© 2012 The Authors. Published by Blackwell Publishing Ltd 5
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(Caulin and Maley 2011). How can large, long-lived
organisms avoid the emergence of cancer or overcome its
progression should it emerge? Few empirical studies have
addressed this question (Seluanov et al. 2008; Gorbunova
and Seluanov 2009). There is also a crucial need to develop
mathematical models to explore theoretically how cancer
vulnerability among wildlife species could have been
shaped by natural selection. The question is by far more
complex than just a problem of body size and longevity –
instead it undoubtedly also depends on the relative impor-
tance to fitness of cancer, infectious and parasitic diseases,
predation, and adverse environmental conditions (Roche
et al. in press). Considering these wildlife species within
their ecosystem could be the missing ingredient to resolve
Peto’s paradox and give critical insights into mechanisms
of cancer resistance. Besides the possible application for
improving cancer prevention for humans, modeling
approaches are a promising way forward for understanding
the impact of cancer in wildlife conservation.
Recent advances have also highlighted that cancer-caus-
ing genes can be maintained in populations through vari-
ous processes. For instance, as for genes reducing survival
in general, natural selection is unlikely to strongly counter-
select oncogenes when their negative effects occur after
reproduction (Frank 2004, 2005; Balducci and Ershler
2005). Additionally, antagonistic pleiotropy might be an
important component in the evolutionary maintenance of
oncogenes (for a review, see Crespi and Summers 2006).
Certain genes indeed have beneficial effects in early life,
when natural selection is strong, but harmful at later ages,
when the effect of selection on evolutionary adaptation
weakens. In the context of cancer, this phenomenon -
antagonistic pleiotropy - has been found in animal models,
perhaps the most stunning case being Xiphophorus fish,
where late life melanoma-promoting oncogene alleles are
associated with early life advantages (Fernandez and Bow-
ser 2010). There is increasing evidence that some human
cancers occurring at later ages may result from negative
trade-offs with early age adaptations (Summers and Crespi
2008, 2010; Smith et al. 2012), such as, for instance, high
birth weight – a life-history trait that has a genetic basis
and is also associated with fitness benefits early in life (e.g.,
survival until maturity, Thomas et al. 2012b; Smith et al.
2012).
Evolution: within-organism selection for cancer cells
Given mounting evidence that neoplasms are characterized
by increased mutation rates, chromosomal anomalies, and
epigenetic alterations, applying evolutionary thinking
to study the proliferation of cancerous cells is crucial
to understanding neoplastic progression. The fitness of
neoplastic cells is shaped by various factors, ranging from
the quantity and the quality of genetic and epigenetic alter-
ations that are beneficial to a neoplastic clone and also by
the interactions with cells and other factors from the local
environment. One of the most promising models for
understanding the role of natural selection in cancer pro-
gression is myeloid malignancies. There may be less genetic
variation and more likelihood for successful treatments
leading to eradication, or at least cancer management. Of
the many mutations that characterize myeloid malignan-
cies, some (TET2, ASXL1) can initiate a preleukemic clone,
whereas others (MPL, JAK2) are phenotypic lesions that
trigger the overt malignant disease (Vainchenker et al.
2011). A preleukemic state may also be the consequence of
germ-line mutations. Thus two preleukemic contexts,
either clonal or polyclonal, driven by somatic or germ-line
lesions, may exist. The degree of overlap between them is
difficult to assess, and initiating events may have subtle
phenotypic consequences for years or decades, before the
actual onset of a full-blown malignancy.
Evolution in solid tumors can differ substantially from
that observed in myeloid cancers. Recent studies have ana-
lyzed the genomic landscape of human colorectal cancers
and identified ~80 nonsilent mutations in individual
tumors, among which <15 were likely to be responsible for
driving the initiation, progression, or maintenance of the
tumor (Sjo¨blom et al. 2006; Wood et al. 2007; Leary et al.
2008; Cancer Genome Atlas Network 2012). These seminal
studies concluded that although alterations in Wnt, K-Ras,
and p53 pathways remain pivotal to tumor formation, a
large number of mutations – each associated with a small
fitness advantage – are likely to be involved in tumor pro-
gression. Future studies will need to consider several addi-
tional, important aspects of evolution in carcinogenesis,
such as (i) When do selected ‘driver’ mutations (Bozic
et al. 2010, Reiter et al. this volume) occur during tumor
formation? (ii) What are the associated qualitative and
quantitative changes in gene expression? (iii) Which genes/
pathways are selected or counter-selected for during tumor
development?
A major challenge in understanding cancerogenesis is
relating process to pattern in malignant and preneoplastic
lesions to untangle the dynamics of cell–cell competition.
This will involve predicting how the host and the grow-
ing neoplasm, which change in time and spatially, affect
signaling networks and have emergent impacts on the
demography and evolution of progressing cancerous
growth. This phenomenon is driven by expression of cer-
tain oncogenes, such as Myc, or tumor suppressors. This
results in overgrowth or in active killing (induction of
apoptosis) of ‘loser’ clone cells by the ‘winner’ clone and
thus evolution. While the role of ‘active competition’ in
tumorigenesis has yet to be demonstrated formally, it has
been confirmed both in the context of mammalian tissue
© 2012 The Authors. Published by Blackwell Publishing Ltd6
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regeneration and in coculture of mammary carcinoma
cell lines (Oertel et al. 2006; Tamori et al. 2010). Specifi-
cally, early work on breast epithelial cancer cell lines
derived from a single spontaneous tumor arising in a
Balb/C mouse demonstrated that the ‘winner’ phenotype
of two related cell lines is independent of their intrinsic
proliferative capacity when cultured alone (Miller et al.
1988). These results were obtained before our current
understanding of apoptosis and of the role of active
cellular competition. They merit reinvestigation in the
context of evolutionary processes.
Evolution: selection for therapeutic resistance during
treatment
Clonal evolution not only selects for increased proliferation
and survival, but is also instrumental in leading to invasion,
metastasis, and therapeutic resistance. Understanding the
costs and benefits of cellular resistance to therapeutic envi-
ronments will constitute a major step forward in improving
treatment outcomes (Martinez-Quintanilla et al. 2009).
A hallmark of myeloid cancers is the ability of the malig-
nant clone to evolve into multiple, frequently more aggres-
sive subclones, as a result of either the natural history of
the disease or the selective pressure of chemotherapy. In
acute myeloid leukemia AML, several pathways involving
the control of proliferation, apoptosis, and chemoresistance
can participate in clonal evolution. Modifications in prolif-
eration advantage have been related to ID1, a common tar-
get of activated tyrosine kinases in chronic and acute
myeloid malignancies (Tang et al. 2009) while leukemic
stem cells express high levels of various ABC proteins
(ABCB1, ABCG2, ABCG1) that protect them from xenobi-
otics (Marzac et al. 2011). Other promising directions
exist. For instance, cyclin-dependent kinases (CDK) are a
new class of therapeutic targets for cancer cells, because
they are required for cell proliferation and are efficiently
inhibited by specific pharmacological agents (Hanahan and
Weinberg 2011). Most importantly, unlike proliferation
arrest induced by DNA damage (irradiation, genotoxic
agents), which may stimulate cancer progression, the cyto-
static effect of CDK inhibitors is direct and, a priori, free of
such undesired side effects. However, as with all chemo-
therapeutic agents, the development of clinical resistance to
CDK inhibitors is likely, and it would be necessary to inves-
tigate the evolution of this resistance. This is sketched in a
theoretical way in the study by Lorz et al. (2012), where it
is shown (by using an adaptive dynamic cell population
model designed to study the evolution of drug resistance)
that it is theoretically possible to overcome resistance in
cancer cell populations (and to eradicate them with
minimal damage to healthy cell populations) by using a
combination of cytotoxic and cytostatic drugs.
Concluding remarks
Ecology and evolution provide a framework for predicting
cancer emergence, progression, and therapies. Phenotypic
evolution of cancers will depend on the complexities of
gene expression (e.g., pleiotropy and epistasis), epigenetic
alterations, and cellular plasticity, all of which interact with
the microenvironment. We can advance toward a predic-
tive science for cancer if we can characterize and measure
(i) demographic parameters (birth and death rates), (ii)
potential (epi)genetic states, their relative fitnesses, and
costs in different microenvironments, and their sequence
of probable appearance, (iii) cellular and tissue functions
(e.g., potential for motility and therefore metastasis), and
(iv) genetic instabilities (aneuploidy, mutation rates). His-
torically, little attention has been focused on applications
of evolutionary biology to understand and control neoplas-
tic progression and to prevent therapeutic failures (Aktipis
et al. 2011). We believe that an accurate evolutionary
approach should unite and explain, rather than replace, the
insights into mechanistic nonevolutionary studies. With
this goal in mind, we are convinced that the topic ‘evolu-
tion and cancer’ is one of the most exciting and challenging
research directions in the effort to understand multicellular
organization and regulation, as well as in applying insights
gained in the ‘war against cancer’.
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